New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 19, 2012
09:32 EDTOGXIOncoGenex announces initiation of Phase 2 OGX-427 study with Zytiga
OncoGenex Pharmaceuticals announced the initiation of PACIFIC, an investigator-sponsored, randomized Phase 2 study evaluating OGX-427 in men with metastatic castrate-resistant prostate cancer who are experiencing a rising PSA while receiving Zytiga. The aim of the study is to determine if adding OGX-427 to Zytiga treatment can reverse or delay treatment resistance. The primary objective will be to compare the two treatment groups for delaying further disease progression while on Zytiga by assessing the progression-free survival rate at 60 days after adding OGX-427. Secondary objectives include comparing the treatment arms for PSA responses, objective responses, time to progression, circulating tumor cells and other biomarkers.
News For OGXI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 19, 2014
08:21 EDTOGXIOncoGenex Phase 2 Borealis-1 trial resulted in 50% reduction in risk of death
OncoGenex Pharmaceuticals announced results from the randomized, controlled Phase 2 Borealis-1 trial evaluating low and high dose apatorsen in combination with gemcitabine/cisplatin chemotherapy compared to chemotherapy alone in the treatment of metastatic bladder cancer. Overall trial results indicated that the addition of 600mg apatorsen to standard of care chemotherapy showed a 14% reduction in risk of death and a 17% reduction in progressive disease and death when compared to chemotherapy alone. Over one-third of the patients in the trial had lower performance status, as defined by a Karnofsky score of 80 percent or less. These patients derived the greatest benefit from 600mg apatorsen in combination with chemotherapy, resulting in a 50% reduction in risk of death compared to chemotherapy alone. Less benefit was observed in the 1000mg apatorsen arm due to increased adverse events leading to a higher rate of discontinuation of both apatorsen and chemotherapy. Apatorsen 600mg was well tolerated in combination with chemotherapy.
December 16, 2014
06:37 EDTOGXIOncoGenex completes patients enrolment for Rainier clinical trial
Subscribe for More Information
December 12, 2014
16:13 EDTOGXIBiotechnology Value Fund reports 6.43% passive stake in OncoGenex

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use